Solid Cancer
Conditions
Brief summary
It has become clear in the recent year that the nature of the immune cells infiltrate within a tumor was essential in the control of the tumor growth. This so-called immune contexture does vary between cancer types and in response to treatments. In this context, this trial is a non-interventional, mono-centric in patients with solid tumors. Samples in paraffin-embedded material block of biopsies or surgical pieces (either primitive tumor or metastases) will be analysed. For each sample, clinically relevant data associated with treated cancer and needed for characterization of tumor microenvironment will be documented. This trial is, through accessing to well documented selected archival tumor materials, to validate selected biomarker for early phase trial.
Interventions
OTHERimmunohistochemistry assay
biomarkers expression
Sponsors
Innate Pharma
Assistance Publique Hopitaux De Marseille
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Sample must have had a valid written informed consent for available archival tumor samples for scientific purposes. * Sample from patients with histologically documented cancer in target population.
Exclusion criteria
* Samples from subject unwilling to give their informed consent; * Unusable sample or biologically deteriorated.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunohistochemistry scores | 24 months | The immunohistochemistry scores is evaluated with the score of the percentage of stained cells. Scale of the score of the percentage of stained cells, From 0 to 4, 0 : no stained cell (absence) 1. : \< 10 % stained cell (minimal) 2. : 10 to 50 % (mild) 3. : 51 to 79 % (moderate) 4. : = or \> 80 % (marked) |
Countries
France
Contacts
Primary ContactBARLESI Fabrice, PU-PH
Outcome results
None listed